| 3.75 0.23 (6.53%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.74 | 1-year : | 5.21 |
| Resists | First : | 4.06 | Second : | 4.46 |
| Pivot price | 3.81  |
|||
| Supports | First : | 3.42 | Second : | 2.84 |
| MAs | MA(5) : | 3.6 |
MA(20) : | 3.81 |
| MA(100) : | 3.28 |
MA(250) : | 2.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 18.9 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 6.94 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZNTL ] has closed above bottom band by 40.8%. Bollinger Bands are 50.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.78 - 3.8 | 3.8 - 3.81 |
| Low: | 3.46 - 3.48 | 3.48 - 3.49 |
| Close: | 3.72 - 3.75 | 3.75 - 3.78 |
Zentalis Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on the discovery and advancement of small molecule therapies designed to treat a range of cancers. The company's pipeline features two primary drug candidates: ZN-c3, an inhibitor of the WEE1 protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. ZN-c3 is currently undergoing various trials, including a Phase 2 study for advanced solid tumors, a Phase 1/2 trial for advanced solid tumors when administered as a monotherapy, and an ongoing Phase 1b trial in conjunction with chemotherapy for patients suffering from platinum-resistant ovarian cancer. Additionally, it is being investigated in a Phase 2 monotherapy trial focused on a tumor-agnostic predictive biomarker. ZN-c5 is in a Phase 1/2 clinical trial aimed at advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced/metastatic breast cancer. Beyond these, Zentalis is developing ZN-d5, a selective B-cell lymphoma 2 inhibitor in Phase 1 clinical trials for non-Hodgkin's lymphoma and acute myelogenous leukemia, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in a Phase 1/2 clinical study for advanced non-small cell lung cancer. The company is also innovating BCL-xL heterobifunctional degraders, specifically designed to utilize E3 ligases not present in platelets, thereby mitigating the dose-limiting thrombocytopenia typically associated with other BCL-xL inhibitors. Incorporated in 2014 and based in New York, New York, Zentalis Pharmaceuticals, Inc. has established licensing agreements and strategic collaborations with partners such as Recurium IP Holdings, LLC, Mayo Foundation for Medical Education and Research, SciClone Pharmaceuticals International (Cayman) Development Ltd., Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
Thu, 11 Jun 2026
Number of shareholders of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Tue, 09 Jun 2026
Zentalis Pharmaceuticals Insider Sellers Vindicated After 10% Drop - simplywall.st
Fri, 05 Jun 2026
ZNTL Should I Buy - Intellectia AI
Mon, 01 Jun 2026
Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Mon, 01 Jun 2026
Cancer drug developer offers 191K stock options to two hires - Stock Titan
Wed, 27 May 2026
Zentalis (ZNTL) director Campbell Shannon files routine Form 3 insider report - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 22.4 (%) |
| Held by Institutions | 62 (%) |
| Shares Short | 4,920 (K) |
| Shares Short P.Month | 5,200 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.7 % |
| Return on Equity (ttm) | -52 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -126 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -2.16 |
| PEG Ratio | 0 |
| Price to Book value | 1.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|